Brainsway Poised for Commercial Launch of Deep TMS in the United States

Brainsway Poised for Commercial Launch of Deep TMS in the United States

JERUSALEM, May 1, 2013 (GLOBE NEWSWIRE) -- Brainsway Ltd. (TASE:BRIN)
("Brainsway" or the "Company") is proud to announce that, after completing
production of approximately 100 Deep TMS systems, it intends to initiate U.S.
commercial sales of the device within the next few days. In addition,
Brainsway has slated the official U.S. marketing launch of Deep TMS for the
American Psychiatric Association ("APA") 2013 Annual Meeting to be held May
18-22 in San Francisco, CA.

In January 2013, the U.S. Food and Drug Administration ("FDA") approved
Brainsway's proprietary Deep TMS device for the treatment of depression in
patients who have failed to respond to antidepressant medications in their
current episode of depression. This approval represented a major breakthrough
for the Company, providing it with access to the U.S. market for depression
therapy, which is valued at tens of billions of dollars per year.

"We are very pleased to have now completed all of the necessary preparations
for a successful commercial launch of Deep TMS in the United States,"
commented Brainsway's CEO, Uzi Sofer."Over the past few months, we have seen
doctor awareness of Deep TMS gain momentum around the world.Indeed, in the
U.S. alone, we have already been contacted by hundreds of psychiatrists who
are interested in incorporating Deep TMS therapy into their practices.We are
looking forward to officially unveiling our technology at the APA meeting."

Mr. Sofer concluded, "The safety and efficacy of depression therapy with
Brainsway's groundbreaking Deep TMS device have been demonstrated extensively
and our excitement continues to grow about the potential Deep TMS treatment
represents in delivering hope for the first time to millions of Americans
suffering from this devastating disease."

About Brainsway Ltd.

Brainsway develops a medical device for the noninvasive treatment of common
brain disorders. The device is based on a uniquely shaped electromagnetic coil
connected to a rapidly changing current supply, which produces magnetic fields
capable of affecting different areas of the brain. Deep brain areas can be
either excited or inhibited, depending on the frequency of the magnetic field.

CONTACT: Stephen Kilmer
         Tel: 212.618.6347
         stephen@kilmerlucas.com